June 22 (Reuters) – Antengene Corp Ltd: * ENTERS EXCLUSIVE LICENSE AGREEMENT WITH K2 THERAPEUTICS FOR ATG-106 * TO RECEIVE ABOUT $20 MILLION UPFRONT AND NEAR-TERM CONSIDERATION Further company
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Rugby-French rugby club Stade Francais reports cyberattack
Aug 6 (Reuters) - Stade Francais said on Thursday that it had been the victim…
Trump likely to reject US industry requests for quicker polysilicon tariff, source says
WASHINGTON, Aug 6 (Reuters) - The Trump administration is expected to spurn requests from some…
Trabzonspor holds signing ceremony for Salah
VIDEO SHOWS: SIGNING CEREMONY FOR MOHAMED SALAH (MO SALAH) HELD IN TRABZONSPOR'S STADIUM / FANS…
